Gilead Sciences has signed an agreement to acquire Repare Therapeutics’ polymerase theta (Polθ) ATPase inhibitor, RP-3467.

The field of cancer treatment saw a variety of advancements in 2025, from new dedicated centers to approved treatments to ...

The Phase 3 AMPLITUDE trial led by UCL found that adding the PARP inhibitor niraparib to standard hormone therapy may slow ...

Hollywood star Angelina Jolie found herself at the center of an online firestorm after a new magazine photoshoot reignited ...

Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to ...

Repare Therapeutics Inc. ("Repare" or the "Company") , a clinical-stage precision oncology company, today announced a definitive asset purchase agreement for Gilead Sciences, Inc. to acquire Repare's ...

London man Dan Godley survived stage three pancreatic cancer with support from his fiancée, a dachshund puppy and groundbreaking treatment. He ...

Mr. Sasse, a former senator from Nebraska, announced that he had received a diagnosis last week for Stage 4 pancreatic cancer ...

Adjuvant carboplatin added to standard anthracycline/taxane chemotherapy significantly improves outcomes in early ...

Angelina Jolie has shockingly faced a torrent of callous online abuse after boldly baring the scars from her double ...

AstraZeneca & Daiichi Sankyo’s Enhertu gets US FDA breakthrough therapy designation in US as post-neoadjuvant therapy for patients with HER2-positive early breast cancer ...

This week Dr. Diana Bitner shares the story of a man she met who is living with breast cancer, and why the holiday season can ...